Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (G Ⅰ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)

Conditions:   Norovirus Infections;   Norwalk Gastroenteritis Interventions:   Biological: Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha);   Biological: placebo Sponsors:   National Vaccine and Serum Institute, China;   Lanzhou Institute of Biological Products Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials